Drug Monograph
Benlysta (Belimumab)
belimumab
Pharmacokinetic Profile
Half-Life
19.4 days (IV); 18.3 days (SC)
Metabolism
Proteolytic degradation (not CYP-mediated)
Protein Binding
Not applicable (monoclonal antibody)
Bioavailability
~74% (SC); 100% (IV)
Volume of Distribution
5.0 L (Vss)
Clinical Information
Drug Class
BLyS-specific inhibitor (human IgG1λ mAb)
Available Doses
IV: 120 mg, 400 mg vials; SC: 200 mg/mL autoinjector/syringe
Route
Intravenous infusion; Subcutaneous injection
Renal Adjustment
None required
Hepatic Adjustment
None required (not formally studied)
Pregnancy
Risk assessment needed; pregnancy registry available
Lactation
Unknown; weigh benefits vs risks
Schedule
Prescription only (not a controlled substance)
Generic Available
No
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Active systemic lupus erythematosus (SLE) | ≥5 years, receiving standard therapy | Add-on to standard therapy | FDA Approved |
| Active lupus nephritis (LN) | ≥5 years, receiving standard therapy | Add-on to standard therapy | FDA Approved |
Belimumab is the first biologic approved specifically for SLE and remains the only biologic with FDA approval for both SLE and lupus nephritis, including in the pediatric population. It is intended for use alongside standard therapies such as corticosteroids, antimalarials, and immunosuppressants. Efficacy has not been established in patients with severe active CNS lupus, and belimumab is not recommended for that setting.
Off-Label Uses
Sjögren syndrome: Small open-label studies and the BELISS trial suggest potential benefit in primary Sjögren syndrome with systemic features, though evidence remains limited. Evidence quality: Low.
Refractory immune thrombocytopenia (ITP): Case series and case reports describe responses in some patients with chronic refractory ITP. Evidence quality: Very low.
Antiphospholipid syndrome (non-thrombotic): Observational data suggest a potential role in non-criteria APS manifestations. Evidence quality: Very low.
Belimumab Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active SLE — intravenous | 10 mg/kg IV on Days 0, 14, 28 | 10 mg/kg IV q4wk | 10 mg/kg | Infuse over 1 hour; consider premedication Do not administer as IV push or bolus |
| Active SLE — subcutaneous | 200 mg SC weekly | 200 mg SC weekly | 200 mg/wk | Abdomen or thigh; first dose supervised Autoinjector or prefilled syringe |
| Active lupus nephritis — intravenous | 10 mg/kg IV on Days 0, 14, 28 | 10 mg/kg IV q4wk | 10 mg/kg | Used with mycophenolate or cyclophosphamide/azathioprine regimens BLISS-LN trial duration: 104 weeks |
| Active lupus nephritis — subcutaneous | 400 mg SC weekly × 4 doses | 200 mg SC weekly | 400 mg/wk (loading); 200 mg/wk (maintenance) | 400 mg = two 200 mg injections at separate sites (≥5 cm apart) Loading dose provides rapid steady-state concentrations from week 2 |
| IV-to-SC switch — SLE | 200 mg SC | 200 mg SC weekly | 200 mg/wk | Give first SC dose 1–4 weeks after last IV dose |
| IV-to-SC switch — lupus nephritis | 200 mg SC | 200 mg SC weekly | 200 mg/wk | Complete at least 2 IV doses before switching; first SC dose 1–2 weeks after last IV dose |
Pediatric Dosing (≥5 Years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active SLE or LN — intravenous | 10 mg/kg IV on Days 0, 14, 28 | 10 mg/kg IV q4wk | 10 mg/kg | Same weight-based dosing as adults |
| Active SLE — SC, ≥40 kg | 200 mg SC weekly | 200 mg SC weekly | 200 mg/wk | Autoinjector only; prefilled syringe not studied in children |
| Active SLE — SC, 15 to <40 kg | 200 mg SC q2wk | 200 mg SC q2wk | 200 mg q2wk | Lower frequency maintains comparable exposures in lower-weight children |
| Active LN — SC, ≥40 kg | 400 mg SC weekly × 4 | 200 mg SC weekly | 400 mg/wk (loading) | Same loading approach as adults |
| Active LN — SC, 15 to <40 kg | 200 mg SC weekly × 4 | 200 mg SC q2wk | 200 mg/wk (loading) | For patients <10 years, must be administered by healthcare provider or trained caregiver |
Clinical Pearl: Reconstitution & Administration
IV belimumab is reconstituted with sterile water to 80 mg/mL, then diluted in 250 mL normal saline (or 100 mL for patients ≤40 kg). Swirl gently — do not shake. The total time from reconstitution to end of infusion should not exceed 8 hours. Dextrose solutions are incompatible with belimumab. SC formulations should be brought to room temperature for 30 minutes before injection.
Pharmacology
Mechanism of Action
Belimumab is a fully human IgG1λ monoclonal antibody that selectively binds to soluble B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF). BLyS is a key cytokine that promotes B-cell survival, differentiation, and class switching. In SLE, elevated BLyS levels are associated with increased autoreactive B-cell activity and autoantibody production. By neutralizing soluble BLyS, belimumab reduces the survival of B cells — including autoreactive clones — and suppresses their maturation into immunoglobulin-secreting plasma cells. Notably, belimumab does not bind B cells directly or deplete them through antibody-dependent cellular cytotoxicity. Clinically, treatment leads to reductions in circulating CD19+, CD20+, naïve, and activated B cells, decreases in anti-dsDNA antibodies and IgG levels, and increases in complement C3 and C4 by as early as 8–12 weeks of therapy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~74%; Tmax ~2.6 days (SC); IV: 100% (direct infusion) | SC route provides comparable steady-state concentrations to IV with weekly dosing; minor fluctuations around Cavg,ss of 104 mcg/mL |
| Distribution | Vss = 5.0 L; distribution t½ = 1.8 days (IV), 1.1 days (SC) | Small Vd consistent with an antibody predominantly confined to the vascular and interstitial space; limited tissue penetration |
| Metabolism | Proteolytic degradation into peptides and amino acids; no CYP involvement | No hepatic drug-metabolising enzyme interactions expected; no dose adjustment for hepatic impairment |
| Elimination | Terminal t½ = 19.4 days (IV), 18.3 days (SC); CL = 215 mL/day (IV), 204 mL/day (SC) | Long half-life supports q4wk IV dosing; pharmacologic effects (B-cell suppression) may persist for weeks to months after discontinuation |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 15% (vs 12% placebo) | More common with IV infusion; usually mild and self-limiting |
| Diarrhea | 12% (vs 9% placebo) | Generally manageable with supportive care |
| Pyrexia | 10% (vs 8% placebo) | Often occurs on infusion day; evaluate for infection if persistent |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 9% (vs 7% placebo) | Part of elevated overall infection rate (71% vs 67% placebo) |
| Bronchitis | 9% (vs 5% placebo) | Monitor for progression; most cases mild upper respiratory tract |
| Insomnia | 7% (vs 5% placebo) | Consider as part of broader psychiatric symptom monitoring |
| Pain in extremity | 6% (vs 4% placebo) | Not typically dose-limiting |
| Depression | 5% (vs 4% placebo) | Screen for suicidal ideation; psychiatric events reported in 16% overall vs 12% placebo |
| Migraine | 5% (vs 4% placebo) | Distinguish from CNS lupus flare |
| Pharyngitis | 5% (vs 3% placebo) | Usually viral; self-limiting |
| Injection site reactions (SC) | 6.1% (vs 2.5% placebo) | Pain, erythema, induration; mild to moderate; rarely requires discontinuation (~6% of affected patients) |
| Cystitis | 4% (vs 3% placebo) | Include UTI in differential for urinary symptoms on therapy |
| Leukopenia | 4% (vs 2% placebo) | Expected pharmacodynamic effect; monitor CBC |
| Viral gastroenteritis | 3% (vs 1% placebo) | Ensure adequate hydration |
Serious
Serious Adverse Effects
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (pneumonia, UTI, cellulitis) | 6.0% (vs 5.2% placebo, SLE trials); 14% in LN trial | Any time during treatment | Consider interrupting belimumab; treat infection aggressively; fatal infections occurred in 0.3% of treated patients |
| Anaphylaxis / severe hypersensitivity | 0.6% (vs 0.4% placebo) | Hours of infusion; can occur after prior tolerability | Discontinue immediately; administer emergency treatment; permanent discontinuation required after anaphylaxis |
| Infusion-related reactions (severe) | 0.5% (vs 0.4% placebo) | During or same day as infusion | Slow or interrupt infusion; administer supportive care; consider premedication for future doses |
| Depression / suicidality | Serious depression: 0.4%; suicides: 0.1% | Any time; assess at baseline and ongoing | Assess suicide risk before and during treatment; consider risk-benefit of continuation; 2 completed suicides in IV trials |
| Progressive multifocal leukoencephalopathy (PML) | Very rare (postmarketing cases) | Variable; weeks to months | Suspend all immunosuppressants immediately if suspected; confirm/exclude PML with MRI and CSF JC virus PCR; discontinue permanently if confirmed |
| Fatal infections | 0.3% (vs 0.1% placebo in SLE trials); 0.45% in postmarketing safety trial | Any time | Evaluate infection risk prior to initiation; maintain high vigilance throughout therapy |
| Fatal anaphylaxis | Very rare (postmarketing) | During/after infusion | Administer in settings prepared for anaphylaxis management |
Discontinuation
Discontinuation Rates
IV Trials (SLE — Adults)
6.2% vs 7.1% placebo
Top reasons: Infusion reactions (1.6%), lupus nephritis (0.7%), infections (0.7%)
SC Trial (SLE — Adults)
7.2% vs 8.9% placebo
Top reasons: Disease progression, adverse events; discontinuation rates actually lower than placebo
| Reason for Discontinuation | Incidence (Belimumab) | Context |
|---|---|---|
| Infusion reactions (IV) | 1.6% | vs 0.9% placebo; most common cause of treatment-related discontinuation |
| Lupus nephritis flare | 0.7% | vs 1.2% placebo; fewer renal flare-related discontinuations with belimumab |
| Infections | 0.7% | vs 1.0% placebo |
Managing Depression and Suicidality
Psychiatric events occurred more frequently with belimumab (16%) than placebo (12%) in IV trials, driven largely by depression and insomnia. Patients should be assessed for psychiatric history and suicide risk before starting treatment. The C-SSRS identified suicidal ideation or behaviour in 2.4% of belimumab-treated patients vs 2.0% on placebo in the postmarketing safety trial. Ongoing mood monitoring at every visit is essential, and patients and caregivers should be counselled to report new or worsening depressive symptoms immediately.
Drug Interactions
No formal drug interaction studies have been conducted with belimumab. As a monoclonal antibody cleared through proteolytic degradation, it does not interact with CYP450 enzymes. Population pharmacokinetic analyses showed no clinically meaningful effect of concomitant corticosteroids, antimalarials, immunosuppressants, NSAIDs, ACE inhibitors, or statins on belimumab pharmacokinetics. The primary interaction concerns relate to additive immunosuppressive effects when combined with other biologic or immunosuppressive therapies.
Major
Rituximab
MechanismDual B-cell targeting leading to profound and prolonged B-cell depletion
EffectIncreased serious infections (9.0% combination vs 2.8% belimumab alone) and post-injection systemic reactions (13.2% vs 9.7%)
ManagementNot recommended; available data do not support concomitant use. If combination is considered, close monitoring for infections is essential
FDA PI — Phase 3 trial data
Major
Other B-cell-targeted biologics
MechanismOverlapping immunosuppressive mechanisms depleting or inhibiting B-cell populations
EffectTheoretical risk of excessive immunosuppression; safety and efficacy not established
ManagementAvoid concomitant use; exercise caution if combination is unavoidable
FDA PI
Major
Live vaccines
MechanismBelimumab suppresses B-cell-mediated immune responses, potentially impairing vaccine efficacy and increasing infection risk
EffectPossible inadequate immune response to live vaccines; risk of vaccine-strain infection
ManagementDo not administer live vaccines for 30 days before or concurrently with belimumab; complete all age-appropriate vaccinations before starting therapy
FDA PI
Moderate
IV Cyclophosphamide
MechanismAdditive immunosuppression with potent alkylating agent
EffectMyelosuppression including febrile neutropenia, leukopenia, and pancytopenia observed in LN trial when cyclophosphamide induction was followed by azathioprine
ManagementStandard of care per BLISS-LN protocol; monitor CBC closely during induction phase
FDA PI — BLISS-LN
Minor
Corticosteroids & ACE Inhibitors
MechanismMild increase in belimumab systemic clearance
EffectMagnitude within normal variability of clearance; not clinically significant
ManagementNo dose adjustment needed; continue standard SLE medications
FDA PI — PopPK analysis
Minor
Inactivated vaccines
MechanismB-cell suppression may reduce humoral response to vaccination
EffectPotentially diminished antibody response to new immunisations
ManagementAdminister inactivated vaccines before starting belimumab when possible; efficacy of vaccination on therapy may be reduced but is not contraindicated
FDA PIMonitoring
-
CBC with differential
Baseline, then q3–6 months
Routine Monitor for leukopenia (reported in 4% of patients). More frequent monitoring warranted if concomitant cyclophosphamide or azathioprine, given reports of myelosuppression including febrile neutropenia. -
Immunoglobulin levels (IgG, IgM)
Baseline, then q6–12 months
Routine Belimumab reduces IgG and IgM levels as a pharmacodynamic effect. Assess for hypogammaglobulinaemia, especially in patients with recurrent infections. -
Renal function & urinalysis
Baseline, then per standard LN protocols
Routine In lupus nephritis, monitor uPCR and eGFR regularly. Proteinuria can increase belimumab clearance, and reductions in proteinuria are a key treatment outcome measure (PERR, CRR endpoints). -
Depression & suicide risk
Baseline, then every visit
Routine Assess psychiatric history before initiation. Use standardised screening tools (e.g., PHQ-9). Instruct patients and caregivers to report new mood changes, suicidal thoughts, or behavioural changes immediately. -
Infection surveillance
Every visit
Routine Overall infection incidence was 71% (vs 67% placebo) in IV trials. Screen for signs of infection including UTI, pneumonia, and bronchitis at each encounter. Consider interrupting therapy for new serious infections. -
Hypersensitivity / infusion reactions
During and after each IV infusion
Trigger-based Monitor throughout infusion and for an appropriate period after. Reactions occurred in 17% of IV recipients (vs 15% placebo). Anaphylaxis can occur even after previous tolerability. Have emergency equipment accessible. -
Neurological status (PML surveillance)
If new neurological symptoms arise
Trigger-based Evaluate any new cognitive, motor, or visual deficits promptly. If PML is suspected, suspend all immunosuppressants and obtain brain MRI and CSF JC virus PCR. -
SLE disease activity
Every 3–6 months
Routine Track anti-dsDNA, complement (C3/C4), and SLEDAI scores. Treatment effect on serological markers (anti-dsDNA reduction, complement normalisation) is typically seen by weeks 8–12.
Contraindications & Cautions
Absolute Contraindications
- Previous anaphylaxis to belimumab: The sole absolute contraindication per the FDA label. Prior anaphylaxis precludes re-challenge regardless of premedication.
Relative Contraindications (Specialist Input Recommended)
- Active severe or chronic infection: The risk-benefit ratio should be carefully weighed. Consider interrupting therapy if a new serious infection develops during treatment.
- Severe active CNS lupus: Efficacy has not been evaluated in this population and belimumab is not recommended for this indication.
- Concurrent biologic therapy (e.g., rituximab, other B-cell agents): Concomitant use increases serious infection rates significantly and is not supported by available data. Specialist co-management required if considered.
- Active or untreated depression with suicidal ideation: The increased psychiatric event rate warrants thorough risk assessment and psychiatric co-management.
Use with Caution
- History of multiple drug allergies or significant hypersensitivity: Limited data suggest these patients may be at increased risk for hypersensitivity reactions.
- Geriatric patients: Insufficient data in patients ≥65 years; use with caution.
- Pregnancy: Monoclonal antibodies cross the placenta, particularly in the third trimester. Animal studies showed reversible B-cell reductions in exposed offspring. Effective contraception recommended during therapy and for at least 4 months after the last dose.
- Patients requiring vaccination: Avoid live vaccines for 30 days before or during therapy. Complete age-appropriate vaccinations before starting treatment. Response to inactivated vaccines may be diminished.
FDA Label Warnings
Serious Infections, Hypersensitivity, Depression & Suicidality, PML
The belimumab prescribing information carries prominent warnings for serious and sometimes fatal infections, hypersensitivity reactions including anaphylaxis and death, depression and suicidality (including completed suicides in clinical trials), and progressive multifocal leukoencephalopathy (PML). These are highlighted in the Warnings and Precautions section rather than as a traditional boxed warning, but they carry the same weight for clinical decision-making. Clinicians must assess infection risk, psychiatric status, and neurological baseline before initiating therapy and maintain vigilance throughout treatment.
Patient Counselling
Purpose of Therapy
Belimumab is a biologic medicine that works by targeting a specific protein (BLyS) involved in the overactive immune response in lupus. It is used alongside your other lupus medications — not instead of them. The goal is to reduce flares, lower disease activity, and potentially allow your doctors to reduce your corticosteroid dose over time. Improvement in disease markers is typically seen within 2–3 months, but the full clinical benefit may take longer.
How to Take
Belimumab can be given either as an intravenous infusion (administered by a healthcare provider over 1 hour, initially every 2 weeks then monthly) or as a weekly subcutaneous injection that you or a caregiver can administer at home after training. Subcutaneous injections should be given in the abdomen or thigh on the same day each week. Allow the autoinjector to reach room temperature for 30 minutes before injection. Rotate injection sites and never inject into bruised, tender, or hard skin.
Infection Risk
Tell patient
Belimumab affects your immune system and may reduce your ability to fight infections. Practice good hand hygiene, avoid close contact with people who are ill, and ensure vaccinations are up to date before starting therapy. Live vaccines cannot be given during treatment.
Call prescriber
If you develop fever, chills, persistent cough, burning with urination, painful or warm skin areas, or any signs that may indicate infection.
Allergic & Infusion Reactions
Tell patient
Some patients experience allergic reactions during or after belimumab administration, including rash, swelling, breathing difficulty, or low blood pressure. Delayed reactions (rash, fatigue, muscle aches) may occur up to a week later. Reactions can happen even if prior doses were tolerated without problem.
Call prescriber
Seek immediate medical attention for difficulty breathing, throat tightness, swelling of face or tongue, severe rash, or dizziness/fainting during or after an infusion or injection.
Mood Changes & Depression
Tell patient
Some patients have experienced new or worsening depression, anxiety, or suicidal thoughts while taking belimumab. This is important to monitor, particularly if you have a history of depression or other mental health conditions.
Call prescriber
Contact your prescriber immediately if you experience new or worsening feelings of sadness, hopelessness, thoughts of self-harm, unusual changes in behaviour, or difficulty sleeping that does not improve.
Neurological Symptoms (PML)
Tell patient
Although extremely rare, a serious brain infection called PML has been reported in patients on immunosuppressive therapies including belimumab. Being aware of the symptoms allows for early detection.
Call prescriber
Report any new or worsening memory problems, confusion, difficulty with balance or walking, vision changes, or difficulty speaking immediately.
Pregnancy & Family Planning
Tell patient
Belimumab may affect the immune system of an unborn baby. Use effective contraception during treatment and for at least 4 months after the last dose. If you are planning pregnancy, discuss timing of discontinuation with your rheumatologist. A pregnancy exposure registry is available (1-877-311-8972).
Call prescriber
Inform your prescriber immediately if you become pregnant or suspect pregnancy while on belimumab.
Missed Doses
Tell patient
If you miss a subcutaneous dose, administer it as soon as you remember. You may then resume your usual weekly schedule or start a new schedule from the day the missed dose was given. Try to give your injection on the same day each week.
Call prescriber
If you have missed more than one dose or are unsure about restarting, contact your prescriber for guidance on resumption.
Sources
Regulatory (PI / SmPC)
- GlaxoSmithKline. BENLYSTA (belimumab) prescribing information. Revised June 2025. GSK PI Primary source for all dosing, safety, pharmacokinetic, and clinical trial data in this monograph.
- FDA. BLA Approval Letter — Benlysta (belimumab). March 9, 2011; supplemental approvals through 2025. FDA Label Documents regulatory history including approvals for SLE (2011), pediatric SLE (2019), lupus nephritis (2020), and pediatric subcutaneous formulations (2024–2025).
Key Clinical Trials
- Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial (BLISS-52). Lancet. 2011;377(9767):721-731. doi:10.1016/S0140-6736(10)61354-2 Pivotal Trial 3 demonstrating SRI-4 response of 58% vs 44% placebo at 52 weeks in active SLE.
- Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus (BLISS-76). Ann Rheum Dis. 2011;70(12):2163-2169. doi:10.1136/ard.2011.153825 Pivotal Trial 2 confirming SRI-4 superiority at 52 weeks (43% vs 34% placebo); treatment difference not maintained at 76 weeks.
- Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis (BLISS-LN). N Engl J Med. 2020;383(12):1117-1128. doi:10.1056/NEJMoa2001180 Landmark Trial 5 supporting LN approval: PERR 43% vs 32% placebo at 104 weeks; 50% reduction in renal events or death.
- Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a 52-week randomized, double-blind, placebo-controlled trial (BLISS-SC). Arthritis Rheumatol. 2017;69(5):1016-1027. doi:10.1002/art.40049 Trial 7 establishing subcutaneous efficacy: SRI-4 of 61% vs 48% placebo, supporting at-home SC administration.
- Brunner HI, Abud-Mendoza C, Bae SC, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (PLUTO). Ann Rheum Dis. 2020;79(10):1340-1348. doi:10.1136/annrheumdis-2020-217101 Trial 6 in pediatric SLE: SRI-4 53% vs 44% placebo; 64% reduction in severe flare risk.
Guidelines
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi:10.1136/ard-2023-224762 Most recent EULAR SLE guideline recommending belimumab as add-on therapy for inadequate response to standard treatment and for steroid sparing.
- Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026;85(1):75-90. doi:10.1016/j.ard.2025.09.007 Updated EULAR guidance supporting belimumab as add-on combination therapy in proliferative lupus nephritis.
- Sammaritano LR, Askanase A, Engel L, et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. Arthritis Care Res. 2025. doi:10.1002/acr.25690 2025 ACR guideline conditionally recommending belimumab for moderate-to-severe non-renal SLE and as therapy escalation for refractory disease.
Mechanistic / Basic Science
- Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253-3265. doi:10.1002/art.11299 Characterisation of the belimumab molecule and its mechanism of BLyS neutralisation.
Pharmacokinetics / Special Populations
- Struemper H, Chen C, Engel S, et al. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711-720. doi:10.1002/jcph.95 Source for population PK parameter estimates: terminal half-life, clearance, and volume of distribution after IV dosing.
- Sheikh SZ, Engel S, Engel L, et al. Pharmacokinetics of subcutaneous belimumab administered to adult subjects with systemic lupus erythematosus. Lupus. 2016;25(13):1456-1464. doi:10.1177/0961203316642312 Characterises subcutaneous PK profile: 74% bioavailability, Tmax 2.6 days, steady-state trough ~97 mcg/mL with weekly dosing.